Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response – UK study – Community News
Covid-19

Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response – UK study

Vials with Pfizer-BioNTech, AstraZeneca and Moderna coronavirus disease (COVID-19) vaccine labels can be seen in this illustration photo, taken March 19, 2021. REUTERS/Dado Ruvic/Illustration

Register now for FREE unlimited access to reuters.com

Dec. 6 (Reuters) – A large UK study into mixing COVID-19 vaccines found that people had a better immune response when given a first dose of AstraZeneca or Pfizer-BioNTech injections, followed by Moderna nine weeks later, according to the results on Monday.

“We found a really good immune response across the board…in fact, higher than the threshold set by the two-dose Oxford-AstraZeneca vaccine,” said Matthew Snape, the Oxford professor behind the trial called Com-COV2. , against Reuters.

The findings supporting flexible dosing will offer some hope to poor and middle-income countries, who may need to combine different brands between first and second injections if supplies run out or become unstable.

Register now for FREE unlimited access to reuters.com

“I think the data from this study will be especially interesting and valuable for low- and middle-income countries where they’re still rolling out the first two doses of vaccines,” Snape said.

“We show… you don’t have to strictly adhere to receiving the same vaccine for a second dose….”

When the AstraZeneca-Oxford (AZN.L) vaccine is followed by a Moderna (MRNA.O) or Novavax (NVAX.O) injection, higher antibodies and T-cell responses were induced versus two doses of AstraZeneca-Oxford, according to researchers. at the University of Oxford.

The study of 1070 volunteers also found that a dose of the Pfizer-BioNTech (PFE.N), (22UAy.DE) vaccine followed by a Moderna (MRNA.O) injection was superior to two doses of the standard Pfizer vaccine. BioNTech cure.

Pfizer-BioNTech followed by Novavax induced higher antibodies than the two-dose Oxford-AstraZeneca schedule, although this schedule induced lower antibody and T-cell responses than the two-dose Pfizer-BioNTech schedule.

No safety concerns have been raised, according to the Oxford University study published in the medical journal Lancet.

Many countries deployed a mix and match long before robust data was available, as security concerns caused countries to contend with rising infection rates, low stocks and slow immunization.

The longevity of vaccine protection has been scrutinized, with booster doses also considered amid rising cases. New variants, including Delta and Omicron, have now increased pressure to accelerate vaccination campaigns.

Blood samples from participants were tested against the Wild-Type, Beta and Delta variants, researchers from the Com-COV2 study said, adding that vaccine efficacy had declined against the variants, but this was consistent across mixed courses.

Deploying vaccines using technology from different platforms – such as the mRNA from Pfizer and Moderna, the viral vector from AstraZeneca and the protein-based injection of Novavax – and within the same scheme is new.

The results may inform new approaches to immunization against other diseases, he said.

The study also found that a first dose of the AstraZeneca-Oxford vaccine followed by one of the other candidates in the study produced a particularly strong response, consistent with the June findings.

The study was designed as a so-called “non-inferiority” study – the intention is to demonstrate that mixing is not significantly worse than the standard schedules – and compares the immune system responses to the gold standard responses reported in previous clinical trials. examining each vaccine.

Register now for FREE unlimited access to reuters.com

Reporting by Pushkala Aripaka in Bengaluru; Editing by Josephine Mason and Mark Heinrich

Our Standards: The Thomson Reuters Trust Principles.

About the author

Rakesh

Add Comment

Click here to post a comment